【摘要】：目的研究2型糖尿病通過(guò)DPP-4抑制劑曲格列汀來(lái)進(jìn)行治療,所取得的臨床應(yīng)用效果,并對(duì)其進(jìn)行評(píng)價(jià)。方法通過(guò)對(duì)我國(guó)以及外國(guó)曲格列汀對(duì)2型糖尿病患者治療的文獻(xiàn)進(jìn)行檢索,將曲格列汀的各個(gè)方面的臨床應(yīng)用進(jìn)行研究和評(píng)價(jià)。結(jié)果 2型糖尿病患者通過(guò)1次/周口服曲格列汀來(lái)進(jìn)行治療和1次/d服用1次阿格列汀來(lái)進(jìn)行治療,2種藥物取得的治療效果大致相同;2型糖尿病患者通過(guò)服用100 mg的曲格列汀,最長(zhǎng)的達(dá)峰時(shí)間為1.3 h,3 d內(nèi)的半衰期平均為18.5 h,7 d內(nèi)的半衰期平均為54.3 h,患者均沒(méi)有產(chǎn)生明顯的蓄積效應(yīng);通過(guò)曲格列汀治療,空腹時(shí)的血糖濃度均得到明顯的降低效果,用食2 h后,患者的血糖濃度與用藥時(shí)曲線下面積(AUC)得到顯著改善,曲格列汀的劑量與效果呈正比;服用曲格列汀后體內(nèi)的的糖化血紅蛋白(HbA1c)含量明顯改善;Ⅱ期劑量研究:患者通過(guò)服用劑量依次增加的曲格列汀,不良反應(yīng)概率達(dá)到:37%、39%、40%、50%、51%,不良反應(yīng)最常見(jiàn)為鼻咽炎,鼻咽炎的程度大多是輕度到中度,其中服用50 mg藥量的患者中小腸結(jié)腸炎患者2例,服用200 mg藥量的患者中糖尿病壞疽患者有2例,Ⅲ期驗(yàn)證研究:常見(jiàn)不良癥狀依舊是輕度或中度鼻咽炎。結(jié)論 2型糖尿病患者通過(guò)服用DPP-4抑制劑曲格列汀,藥物療效顯著,該藥在臨床上的應(yīng)用具有重要意義。
[Abstract]:Objective to study the clinical effects of treatment of type 2 diabetes mellitus (T2DM) by DPP-4 inhibitor trasiglitine and to evaluate the clinical efficacy of Teglitine in the treatment of type 2 diabetes mellitus. Methods the clinical application of trasiglitine in patients with type 2 diabetes mellitus was studied and evaluated by searching the literature on the treatment of type 2 diabetes mellitus in China and foreign countries. Results patients with type 2 diabetes were treated with trasiglitine once a week and aceglitine once a day. The therapeutic effects of the two drugs were approximately the same. The longest peak time of type 2 diabetic patients was 1.3h, the average half-life within 3 days was 18.5 hours, and the average half-life within 7 days was 54.3 hours. There was no significant accumulative effect in patients with type 2 diabetes mellitus. After 2 hours of treatment, the blood glucose concentration of the patients was significantly improved with the area under the curve of treatment (AUC), and the dose of trasiglitine was in direct proportion to the effect. 2 hours after the treatment, the blood glucose concentration of the patients was significantly improved with the decrease of the fasting blood glucose concentration. The content of glycosylated hemoglobin (HbA1c) in the body was significantly improved after the administration of trasiglitine. Phase II dose study: the adverse reaction probability was 37%, 39%, 40%, 50%, 51%, and the most common side effects were nasopharyngitis, and the degree of nasopharyngitis was mostly mild to moderate, and the adverse reaction probability was 37%, 39%, 40%, 50%, 51%. Among them, 2 patients with enterocolitis and 2 patients with diabetes gangrene were treated with 50 mg and 2 patients with diabetes gangrene. Phase 鈪，

本文編號(hào)：2444601